A seven-year medical research study reported that women whose mothers took the drug DES during pregnancy were twice as likely to
develop tissue abnormalities that might lead to cancer as were women whose mothers did not take the drug. This study compared two populations. What were the populations
In the study, there are two separate groups: "Women whose mothers took the drug DES during pregnancy" and "Women whose mothers didn't take the drug during pregnancy" these two groups represent the populations of interest.
